ClinicalTrials.gg
Enrolling by invitationNCT07255768Updated Dec 8, 2025

Comparison of the Efficacy of Pericapsular Nerve Group Block Alone Versus Pericapsular Nerve Group Block Combined With Superior Cluneal and Superior Gluteal Nerve Blocks in Patients Undergoing Hip Surgery

An interventional study of 15 ml Bupivacaine Hcl 0.25% injection and 20 mL bupivacaine 0.25% injection in Hip Osteoarthritis, Osteonecrosis of the Femoral Head and Avascular Necrosis of Femur Head, sponsored by Ataturk University. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Ataturk University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Osteoarthritis, Hip with a site in Turkey — 5 open to participants now, 5 under way, none of them phase 3. Osteoarthritis, Hip · Turkey.

Planned enrollment
7th of 18
60 · median 60
Started
2025
with 3 others
No phase
18 of 27
4 open now
Registered
21st of 27
by date
Lead sponsor
1 of 27
Ataturk University

Among the 27 studies in Osteoarthritis, Hip with a site in Turkey, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 with no phase, and was the 21st registered.

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

5 of the 27 studies in Osteoarthritis, Hip with a site in Turkey are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Osteoarthritis, Hip with a site in Turkey, or all of them as a file.
02

Study summary

In the clinic, total hip arthroplasty is a frequently performed surgical procedure that often results in moderate to severe postoperative pain. Multimodal analgesia approaches are commonly preferred for managing this pain, and in recent years, nerve blocks targeting pelvic innervation have become increasingly prominent. Among these, the Pericapsular Nerve Group (PENG) block has gained attention for providing effective analgesia by targeting the nerves responsible for the anterior innervation of the hip capsule. However, when used alone, the PENG block may be insufficient for controlling posterior hip pain and may not provide complete analgesia.

In this context, adding blocks targeting the superior cluneal nerve and the superior gluteal nerve-both of which contribute to the sensory innervation of the posterior hip region-has been proposed to enhance the analgesic effect when combined with the PENG block. Superior cluneal and superior gluteal nerve blocks have recently been described in anatomical and clinical studies, and by affecting the structures contributing sensory input to the posterior hip capsule, they hold significant potential for improving pain management.

In this study, the investigators aimed to evaluate the contribution of superior cluneal and superior gluteal nerve blocks, when added to the PENG block, to perioperative analgesia in patients undergoing total hip arthroplasty. The investigators sought to comparatively investigate whether this combination offers superior outcomes compared with the PENG block alone. It was hypothesized that combined nerve blocks may provide similar or improved recovery scores, lower pain scores, reduced opioid consumption, and enhanced analgesic efficacy without affecting the degree of motor blockade.

03

Conditions studied

  • Hip Osteoarthritis
  • Osteonecrosis of the Femoral Head
  • Avascular Necrosis of Femur Head
  • Dysplasia of Hip Joint
  • Hip Surgeries
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation in the study
  • Age between 18 and 80 years
  • I, II, or III
  • Male or female patients

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
  • Allergy to the medications to be used
  • History of severe cardiac, renal, or hepatic disease
  • Presence of neurological deficits or neuropathy
  • History of anticoagulant use
  • Previous surgery in the inguinal or suprainguinal region
  • Pregnancy
  • Chronic opioid use at home
  • History of spinal surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Application of PENG Block

    Patients will be brought to the operating room one hour before surgery, and no premedication will be administered prior to their arrival. Before performing the PENG block, patients will be placed in the supine position. The ultrasound probe will be positioned in the transverse plane medial and caudal to the anterior superior iliac spine, and the anterior inferior iliac spine, iliopubic eminence, and psoas tendon will be identified. Using an in-plane technique, the needle will be advanced from lateral to medial and positioned between the psoas tendon and the periosteum. After negative aspiration, 15 mL of 0.25% bupivacaine will be administered.

    Drug: 15 ml Bupivacaine Hcl 0.25% injection · Drug: 20 mL bupivacaine 0.25% injection

  • Active comparator
    Application of PENG Block together with Superior Cluneal and Superior Gluteal Nerve Blocks

    All patients will receive a PENG block, and in addition: The superior cluneal nerve block will be performed at the level of the posterior iliac crest under ultrasound guidance, along the course of the nerve, using 10 mL of 0.25% bupivacaine. The superior gluteal nerve block will be administered in the lateral decubitus position under ultrasound guidance, with 10 mL of 0.25% bupivacaine injected between the gluteal muscles along the trajectory of the nerve.

    Drug: 20 mL bupivacaine 0.25% injection

Interventions

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For PENG Block, 15 mL of 0.25% bupivacaine will be administered.

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After performing PENG; 10 mL of 0.25% bupivacaine will be administered for each superior cluneal nerve block and superior gluteal nerve block

06

What researchers measure

Primary outcomes

  1. QoR-15 (Quality of Recovery-15) questionnaire

    The primary outcome measure will be the QoR-15 (Quality of Recovery-15) questionnaire administered at the 24th postoperative hour. QoR-15 is a validated 15-item short survey assessing patients' postoperative physical comfort, emotional state, level of independence, pain control, and overall well-being. The total score obtained will be used to compare the overall quality of recovery between groups. The same questionnaire will be repeated at the 48th postoperative hour.

    Time frame: 24th and 48th postoperative hour

Secondary outcomes

  1. Quadriceps Motor Block Assessment

    Motor block will be assessed using the following 3-point scale: 0 = Normal strength (dorsiflexion against gravity and resistance) 1. = Paresis (dorsiflexion against gravity only, not against resistance) 2. = Paralysis (dorsiflexion not possible)

    Time frame: It will be assessed at the 4th, 8th, 12th, and 24th postoperative hours.

  2. Motor Block Assessment at the Tibialis Anterior Muscle for the Sciatic Nerve

    Motor block will be assessed using the following 3-point scale: 0 = Normal strength (dorsiflexion against gravity and resistance) 1. = Paresis (dorsiflexion against gravity only, not against resistance) 2. = Paralysis (dorsiflexion not possible)

    Time frame: It will be assessed at the 4th, 8th, 12th, and 24th postoperative hours.

  3. Fentanyl consumption

    Fentanyl consumption will be recorded via the PCA device during the postoperative intervals of 0-4, 4-8, and 8-24 hours. Total opioid consumption will be calculated at the 24th postoperative hour.

    Time frame: The first 24 postoperative hours

  4. VAS pain scores

    VAS pain scores will be assessed at the 1st, 2nd, 4th, 8th, 12th, and 24th postoperative hours, both at rest and during movement. The region where the patient experiences the most intense pain will be recorded as either the anterior or posterior hip.

    Time frame: The first 24 postoperative hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.

Of 201 non-industry interventional studies with no phase under Osteoarthritis, Hip, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 29 months; a quarter within 14 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Dec 1, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Sep 2026
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07255768
Lead sponsor
Ataturk University
Responsible party
Ahmet Murat Yayik (Principal Investigator, Ataturk University) — Principal investigator
First posted
Dec 1, 2025
Start date
Sep 1, 2025
Primary completion
Aug 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Dec 8, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion